INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 416m ago
HOUSE PTR16m ago
SEC 13F16m ago
ROBINHOOD CHAIN16m ago
Public company

BDXBECTON DICKINSON & CO

CIK 0000010795

EDGAR filingsOpen in network
Disclosed transactions13
Buys / sells0 / 8
Max Insider Score24
Connections12with evidence

BDX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
1
FM
Feld MichaelEVP, Chief Revenue Officer
BDXBECTON DICKINSON & CO
Open-market sale · 10b5-1 plan
SELL$15K
76 sh
Oct 26, 2026Oct 27, 2026
traded Oct 26, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 3841 · Surgical & Medical Instruments & Apparatus · Nov 4, 2026
  • ← Lobbied forevidence
    SQUIRE PATTON BOGGSLDA 1TY 2026 first quarter · issues not listed · Aug 26, 2026
  • ← Lobbied forevidence
    DCI GROUP, L.L.C.LDA Q1 2026 first quarter · TAR · Aug 26, 2026
  • ← Lobbied forevidence
    BECTON, DICKINSON AND COMPANYLDA Q1 2026 first quarter · Trade, Medicare/Medicaid, Health issues, Taxation, Budget/appropriations · Aug 26, 2026
1
FM
Feld MichaelEVP, Chief Revenue Officer
BDXBECTON DICKINSON & CO
Open-market sale · 10b5-1 plan
SELL
$14K
76 sh
Sep 28, 2026
Sep 29, 2026
traded Sep 28, 2026
+1d
SEC FORM 4

Evidence

5
FM
Feld MichaelEVP, Chief Revenue Officer
BDXBECTON DICKINSON & CO
Open-market sale · 10b5-1 plan
SELL$11K
75 sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

20
Thomas H. Kean, Jr.RSelf
BDXBECTON DICKINSON & CO
Sale
SELL$1,001 – $15KMay 21, 2026Jun 18, 2026
traded May 21, 2026
+28dHOUSE PTR

Evidence

24
Kevin HernRJoint
BDXBECTON DICKINSON & CO
Sale
SELL$15K – $50KMar 17, 2026Apr 3, 2026
traded Mar 17, 2026
+17dHOUSE PTR

Evidence

9
SL
Spikner Pamela L.SVP Controller & CAO
BDXBECTON DICKINSON & CO
Tax withholding
F—
84 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

13
GD
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm
BDXBECTON DICKINSON & CO
Option exercise · 10b5-1 plan
M$513K
3,054 sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

13
GD
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm
BDXBECTON DICKINSON & CO
Disposition to issuer · 10b5-1 plan
D$513K
2,454 sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

8
GD
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm
BDXBECTON DICKINSON & CO
Open-market sale · 10b5-1 plan
SELL$125K
600 sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

12
GD
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm
BDXBECTON DICKINSON & CO
Open-market sale · 10b5-1 plan
SELL$209K
1,010 sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

0
GD
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm
BDXBECTON DICKINSON & CO
Option exercise · 10b5-1 plan
M—
3,054 sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

9
SD
Shan DavidEVP and Chief ISC Officer
BDXBECTON DICKINSON & CO
Tax withholding
F—
44 sh
Jan 3, 2026Jan 6, 2026
traded Jan 3, 2026
+3dSEC FORM 4

Evidence

21
SL
Scott Bertram LDirector
BDXBECTON DICKINSON & CO
Open-market sale
SELL$38K
217 sh
Nov 7, 2025Nov 7, 2025
traded Nov 7, 2025
+0dSEC FORM 4

Evidence

  • ← Lobbied forevidence
    BGR GOVERNMENT AFFAIRSLDA Q2 2026 second quarter · TAR · Aug 26, 2026
  • ← Insider ofevidence
    Feld MichaelEVP, Chief Revenue Officer · Jun 26, 2026
  • ← Disclosed trade inevidence
    Thomas H. Kean, Jr.Sale disclosed 2026-06-18 · Jun 18, 2026
  • ← Disclosed trade inevidence
    Kevin HernSale disclosed 2026-04-03 · Apr 3, 2026
  • ← Insider ofevidence
    Spikner Pamela L.SVP Controller & CAO · Jan 23, 2026
  • ← Insider ofevidence
    Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm · Jan 16, 2026
  • ← Insider ofevidence
    Shan DavidEVP and Chief ISC Officer · Jan 6, 2026
  • ← Insider ofevidence
    Scott Bertram LDirector · Nov 7, 2025

    • Lobbying

    $1.66M reported · de-duplicated
    2026 Q2 $762K via firms2026 Q1 $895K via firms
    • SQUIRE PATTON BOGGS—2026 Q1 · posted Aug 26, 2026 ·
    • DCI GROUP, L.L.C.$60K2026 Q1 · posted Aug 26, 2026 · TAR
    • BECTON, DICKINSON AND COMPANY$622K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues, Taxation, Budget/appropriations, Trade
    • BGR GOVERNMENT AFFAIRS$80K2026 Q1 · posted Aug 26, 2026 · TAR
    • DCI GROUP, L.L.C.$60K2026 Q2 · posted Aug 26, 2026 · TAR
    • BECTON, DICKINSON AND COMPANY$755K2026 Q1 · posted Aug 26, 2026 · Trade, Medicare/Medicaid, Health issues, Taxation, Budget/appropriations
    • BGR GOVERNMENT AFFAIRS$80K2026 Q2 · posted Aug 26, 2026 · TAR

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.